Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

236 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-11-23

Study Completion Date

2020-05-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate the efficacy of the new treatment of WH-1 ointment compared to Aquacel® Hydrofiber® dressing, applied to chronic diabetic foot ulcers for up to 16 weeks.An additional objective of this study is to collect safety information including adverse events and clinical laboratory abnormalities.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Randomized,Double-blind,Placebo-controlled Clinical Study to Explore the Mechanism of Action of ON101 Cream in Patients With DFUs.

NCT04945161

Diabetic Foot Ulcers

COMPLETED NA

Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers

NCT04962139

Chronic Diabetic Foot Ulcers

TERMINATED PHASE3

Retrospective Record-review Study in Patients Who Had Diabetic Foot Ulcer

NCT05135130

Diabetic Foot Ulcer

UNKNOWN

Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers

NCT00709514

Chronic Diabetic Foot Ulcer

COMPLETED PHASE2

The Pharmacokinetic Study of WH-1 Ointment in Subjects With Chronic Diabetic Foot Ulcers

NCT02353273

Diabetic Foot

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial is designed as a randomized, evaluator blinded, active-controlled, multi-center study comparing the efficacy and safety of WH-1 ointment and Aquacel® Hydrofiber® dressing in the treatment of diabetic foot ulcers. Independent evaluators who blinded to subjects' treatment will evaluate whether the wound has healed. Eligible subjects will be randomized to receive either WH-1 ointment or Aquacel® Hydrofiber® dressing in a 1:1 allocation. The study treatment will be applied to the selected ulcer for a maximum period of 16 weeks, until the wound/ulcer closure (wound size of 0) for two consecutive visits at least 2 weeks apart, or until the subject exited the study as treatment failure. After that, all subjects regardless of wound healing at the end of comparison period will be followed for 12 weeks to investigate durability. During the follow-up period, Aquacel® Hydrofiber® dressing will be applied for subjects who have unhealed or with recurrent wound. Each target ulcer with wound photographs for blind assessment will be monitored at each scheduled visit.

One interim analysis is planned at around 50% of study information; the final analysis will be conducted at the end of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Foot

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ON101 Cream

ON101 Cream (1.25%),15g ointment per tube. Twice daily for up to 16 weeks.

Group Type EXPERIMENTAL

ON101 Cream

Intervention Type DRUG

Aquacel® Hydrofiber® dressing

Aquacel® Hydrofiber® dressings will be changed daily, on alternate days or three times a week according to need, but not longer than 7 days.

Group Type OTHER

Aquacel® Hydrofiber® dressing

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ON101 Cream

Intervention Type DRUG

Aquacel® Hydrofiber® dressing

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

WH-1

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Has signed a written informed consent prior to the first study evaluation;
2. Male or female is at least 20 and \< 80 years of age;
3. Diabetes mellitus (type 1 or 2) with an HbA1c \< 12.0% measured during screening or within three months prior to randomization;
4. An ankle brachial index on the target limb at least 0.8 measured during screening or within three months prior to randomization;
5. The target ulcer must have the following characteristics:

* Grade 1 or 2 per Wagner Ulcer Classification System;
* No higher than the ankle;
* No active infected;
* A cross-sectional area of between 1 and 25 cm2 post-debridement;
* Present for at least 4 weeks before randomization;
6. If female and of childbearing potential has a negative pregnancy test and is not breastfeeding at screening visit;
7. Able and willing to attend the scheduled visits and comply with study procedures.

Exclusion Criteria

1. Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement;
2. Acute Charcot's neuroarthropathy as determined by clinical and/or radiographic examination;
3. Has undergone revascularization procedure aimed at increasing blood flow in the treatment target limb \< 4 weeks prior to randomization;
4. Poor nutritional status defined as an albumin \< 2.5 g/dL;
5. Aspartate Aminotransferase(AST, GOT) and/or Alanine Aminotransferase(ALT, GPT) \>3 x the normal upper limit;
6. Serum Creatinine \>2 x the normal upper limit;
7. Treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 4 weeks before randomization;
8. Use of any investigational drug or therapy within the 4 weeks prior to randomization;
9. A psychiatric condition (e.g., suicidal ideation), current or chronic alcohol or drug abuse problem, determined from the subject's medical history, which, in the opinion of the Investigator, may pose a threat to subject compliance;
10. Judged by the investigator not to be suitable for the study for any other reason.

Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No